222 related articles for article (PubMed ID: 19462434)
1. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders.
Jeffery J; Lewis SJ; Ayling RM
Inflamm Bowel Dis; 2009 Nov; 15(11):1630-4. PubMed ID: 19462434
[TBL] [Abstract][Full Text] [Related]
2. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study.
Shastri YM; Povse N; Schröder O; Stein J
Clin Lab; 2008; 54(9-10):389-90. PubMed ID: 19097497
[No Abstract] [Full Text] [Related]
4. Determination of faecal inflammatory marker concentration as a noninvasive method of evaluation of pathological activity in children with inflammatory bowel diseases.
Roszak D; Gałęcka M; Cichy W; Szachta P
Adv Med Sci; 2015 Sep; 60(2):246-52. PubMed ID: 25989184
[TBL] [Abstract][Full Text] [Related]
5. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
Sidler MA; Leach ST; Day AS
Inflamm Bowel Dis; 2008 Mar; 14(3):359-66. PubMed ID: 18050298
[TBL] [Abstract][Full Text] [Related]
6. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
[TBL] [Abstract][Full Text] [Related]
7. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders.
Caviglia GP; Pantaleoni S; Touscoz GA; Adriani A; Rosso C; Smedile A; Pellicano R; Astegiano M; Bresso F
Scand J Gastroenterol; 2014 Dec; 49(12):1419-24. PubMed ID: 25369978
[TBL] [Abstract][Full Text] [Related]
8. Fecal pyruvate kinase is not suitable for discrimination between inflammatory bowel disease exacerbation and acute gastroenteritis.
Czub E; Nowak JK; Moczko J; Mankowski P; Lisowska A; Banaszkiewicz A; Banasiewicz T; Walkowiak J
Dev Period Med; 2015; 19(2):167-73. PubMed ID: 26384117
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity.
Czub E; Nowak JK; Szaflarska-Poplawska A; Grzybowska-Chlebowczyk U; Landowski P; Moczko J; Adamczak D; Mankowski P; Banasiewicz T; Plawski A; Walkowiak J
Acta Biochim Pol; 2014; 61(1):99-102. PubMed ID: 24649481
[TBL] [Abstract][Full Text] [Related]
10. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation.
Mooiweer E; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
Inflamm Bowel Dis; 2014 Feb; 20(2):307-14. PubMed ID: 24374878
[TBL] [Abstract][Full Text] [Related]
11. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin.
Vázquez Morón JM; Pallarés Manrique H; Machancoses FH; Ramos Lora M; Ruiz Frutos C
Rev Esp Enferm Dig; 2017 Feb; 109(2):130-136. PubMed ID: 28071062
[TBL] [Abstract][Full Text] [Related]
12. Elevated fecal M2-pyruvate kinase in children with cystic fibrosis: a clue to the increased risk of intestinal malignancy in adulthood?
Pang T; Leach ST; Katz T; Jaffe A; Day AS; Ooi CY
J Gastroenterol Hepatol; 2015 May; 30(5):866-71. PubMed ID: 25376228
[TBL] [Abstract][Full Text] [Related]
13. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms.
Fagerberg UL; Lööf L; Myrdal U; Hansson LO; Finkel Y
J Pediatr Gastroenterol Nutr; 2005 Apr; 40(4):450-5. PubMed ID: 15795593
[TBL] [Abstract][Full Text] [Related]
14. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in acute diarrhea in hospitalized children.
Czub E; Nowak JK; Moczko J; Lisowska A; Banaszkiewicz A; Banasiewicz T; Walkowiak J
Sci Rep; 2014 Apr; 4():4769. PubMed ID: 24759699
[TBL] [Abstract][Full Text] [Related]
15. Faecal calprotectin in the diagnosis of inflammatory bowel disease.
Burri E; Beglinger C
Biochem Med (Zagreb); 2011; 21(3):245-53. PubMed ID: 22420238
[TBL] [Abstract][Full Text] [Related]
16. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
17. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313
[TBL] [Abstract][Full Text] [Related]
18. Fecal calprotectin in pediatric inflammatory bowel disease: a systematic review.
Kostakis ID; Cholidou KG; Vaiopoulos AG; Vlachos IS; Perrea D; Vaos G
Dig Dis Sci; 2013 Feb; 58(2):309-19. PubMed ID: 22899243
[TBL] [Abstract][Full Text] [Related]
19. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
[TBL] [Abstract][Full Text] [Related]
20. Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders.
Lozoya Angulo ME; de Las Heras Gómez I; Martinez Villanueva M; Noguera Velasco JA; Avilés Plaza F
Gastroenterol Hepatol; 2017 Mar; 40(3):125-131. PubMed ID: 27260632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]